Skip to main content

Table 1 Patient characteristics

From: Use, tolerability and compliance of spironolactone in the treatment of heart failure

 

CHF

n = 82 018

CHF using spironolactone

n = 12,344

Age group

  

   <20

518 (0.6%)

11 (0.1%)

   20-39

1,366 (1.7%)

62 (0.5%)

   40-59

6,114 (7.5%)

716 (5.8%)

   60-79

31,499 (38.4%)

5,093 (41.3%)

   80+

42,521 (51.8%)

6,462 (52.3%)

Average age (SD)

77.2 (14.1)

78.5 (11.4)

Gender

  

   - male

39,132 (47.7%)

6,368 (51.6%)

   - Female

42,886 (52.3%)

5,976 (48.4%)

Average Von Korff score (SD)

7.6 (3.4)

8.8 (2.9)

Selected drug use

  

   - ACE

49,140 (59.9%)

9,493 (76.9%)

   - ARB

23,326 (28.4%)

4,455 (36.1%)

   - β-blocker

48,772 (59.5%)

9,260 (75.0%)

Concomitant use with

  

   - ACE

 

6,702 (54.3%)

   - ARB

 

2,654 (21.5%)

   - β-blocker

 

7,217 (58.5%)